ନାବିଲୋନ

ନାବିଲୋନ
	Top: (R,R)-(−)-nabilone,; Center: (S,S)-(+)-nabilone,; Bottom: Space-filling model of (R,R)-(−)-nabilone
Clinical data
Trade names	Cesamet, Canemes
AHFS/Drugs.com	monograph
MedlinePlus	a607048
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	AU: S8 (Controlled) ; CA: Schedule II ; DE: Anlage III (Prescription only) ; UK: POM (Prescription only) ; US: Schedule II ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	20% after first-pass by the liver
Protein binding	similar to THC (±97%)
Elimination half-life	2 hours, with metabolites around 35 hours
Identifiers
	IUPAC name rel-(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one;
ECHA InfoCard	100.164.824
Chemical and physical data
Formula	C24H36O3
Molar mass	୩୭୨.୫୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3CC[C@@H]1[C@H](c2c(OC1(C)C)cc(cc2O)C(C)(C)CCCCCC)C3;
	InChI InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1 ; Key:GECBBEABIDMGGL-RTBURBONSA-N ;
(verify)

ନାବିଲୋନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନମ ସେସାମେଟ, ହେଉଛି ଏକ ଔଷଧ ଯାହା କେମୋଥେରାପି ଜନିତ ଅଇ ଓ ବାନ୍ତିର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଫାଇବ୍ରୋମ୍ୟାଲ୍‌ଜିଆ ଏବଂ ମଲ୍ଟିପ୍ଲ ସ୍କ୍ଲେରୋସିସ ପାଇଁ କିଛି କାର୍ଯ୍ୟକାରିତାକୁ ପ୍ରମାଣ ସ‌ହିତ ସମର୍ଥନ କରେ ।^[୨] ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରା, ଶୁଷ୍କ ପାଟି, ମୁଣ୍ଡ ବୁଲାଇବା, ଇଉଫୋରିଆ, ସମନ୍ୱୟ ଅଭାବ ଏବଂ ମୁଣ୍ଡବିନ୍ଧା ହୋଇପାରେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଦ୍ରୁତ ହୃଦସ୍ପନ୍ଦନ, ଅପବ୍ୟବହାର ଏବଂ ସାଇକୋସିସ୍ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୧] ଏହା ଏକ ସିନ୍ଥେଟିକ୍ କାନାବିନଏଡ଼ ଯାହା କାନାବିସରେ ମିଳୁଥିବା ପ୍ରାଥମିକ ସାଇକୋଆକ୍ଟିଭ ଯୌଗିକ ପଦାର୍ଥ ଭଳି ଟେଟ୍ରାହାଇଡ୍ରୋକାନାବିନୋଲ୍ର (THC) ଅନୁରୂପ ପ୍ରଭାବ ମିଳେ ।^[୧] ^[୫]

୧୯୮୫ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ବ୍ୟବହାର ପାଇଁ ନାବିଲୋନ ଅନୁମୋଦିତ ହୋଇଥିଲା ^[୧] ଯୁକ୍ତରାଜ୍ୟରେ ୧ମିଗ୍ରା ବିଶିଷ୍ଟ ୨୦ ବଟିକାର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ୨୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ମୂଲ୍ୟ ୮୨୦ ଡଲାର ଥିଲା ।^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଏକ ସିଡ୍ୟୁଲ୍ଲ ୨ ନିୟନ୍ତ୍ରିତ ପଦାର୍ଥ ।^[୧]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Nabilone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 October 2020. Retrieved 11 November 2021.
↑ Fine PG, Rosenfeld MJ (2013). "The endocannabinoid system, cannabinoids, and pain". Rambam Maimonides Medical Journal (Review). 4 (4): e0022. doi:10.5041/RMMJ.10129. PMC 3820295. PMID 24228165.
↑ Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. PMID 29442178. {{cite journal}}: |hdl-access= requires |hdl= (help)
↑ ^୪.୦ ^୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 451. ISBN 978-0857114105.
↑ "DailyMed - CESAMET- nabilone capsule". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 11 November 2021.
↑ "Cesamet Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 9 April 2021. Retrieved 11 November 2021.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Nabilone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 October 2020. Retrieved 11 November 2021.

[Fine2013-2] Fine PG, Rosenfeld MJ (2013). "The endocannabinoid system, cannabinoids, and pain". Rambam Maimonides Medical Journal (Review). 4 (4): e0022. doi:10.5041/RMMJ.10129. PMC 3820295. PMID 24228165.

[3] Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. PMID 29442178. {{cite journal}}: |hdl-access= requires |hdl= (help)

[BNF81-4] ୪.୦ ^୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 451. ISBN 978-0857114105.

[PI2021-5] "DailyMed - CESAMET- nabilone capsule". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 11 November 2021.

[6] "Cesamet Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 9 April 2021. Retrieved 11 November 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

Clinical data

Top: (R,R)-(−)-nabilone, Center: (S,S)-(+)-nabilone, Bottom: Space-filling model of (R,R)-(−)-nabilone
Trade names	Cesamet, Canemes
AHFS/Drugs.com	monograph
MedlinePlus	a607048
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	By mouth (capsules)
Legal status
Legal status	AU: S8 (Controlled) CA: Schedule II DE: Anlage III (Prescription only) UK: POM (Prescription only) US: Schedule II ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20% after first-pass by the liver
Protein binding	similar to THC (±97%)
Elimination half-life	2 hours, with metabolites around 35 hours
Identifiers
IUPAC name rel-(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one
ECHA InfoCard	100.164.824
Chemical and physical data
Formula	C₂₄H₃₆O₃
Molar mass	୩୭୨.୫୫ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C3CC[C@@H]1[C@H](c2c(OC1(C)C)cc(cc2O)C(C)(C)CCCCCC)C3
InChI InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1^Y Key:GECBBEABIDMGGL-RTBURBONSA-N^Y
(verify)